APO Research
Talk to an analyst

APO RESEARCH · REPORT

Bi-Specific Antibodies Therapy

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Bi-Specific Antibodies Therapy Market Analysis and Forecast 2026-2032

29 December 2025193 pages

Choose your research edition.

Industry ResearchBi-Specific Antibodies Therapy Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Bi-Specific Antibodies Therapy Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Bi-Specific Antibodies Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Bi-Specific Antibodies Therapy Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Bi-Specific Antibodies Therapy Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Bi-Specific Antibodies Therapy market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Bi-Specific Antibodies Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Bi-Specific Antibodies Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Bi-Specific Antibodies Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Bi-Specific Antibodies Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Bi-Specific Antibodies Therapy include Alphamab Co. Ltd, Genmab, Lindis Biotech, MacroGenics, Inc, AstraZeneca, AbbVie, Amgen, Pfizer and Akeso, Inc., etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Bi-Specific Antibodies Therapy, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Bi-Specific Antibodies Therapy, also provides the revenue of main regions and countries. Of the upcoming market potential for Bi-Specific Antibodies Therapy, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Bi-Specific Antibodies Therapy revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Bi-Specific Antibodies Therapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Bi-Specific Antibodies Therapy revenue, projected growth trends, production technology, application and end-user industry.

Bi-Specific Antibodies Therapy Segment by Company

Alphamab Co. Ltd

Genmab

Lindis Biotech

MacroGenics, Inc

AstraZeneca

AbbVie

Amgen

Pfizer

Akeso, Inc.

Roche

Johnson & Johnson

Sanofi

Bi-Specific Antibodies Therapy Segment by Type

Fragment-Based Antibodies

IgG-Based Antibodies

Bi-Specific Antibodies Therapy Segment by Application

Cancer

Haemophilia

Other Non-Cancer Diseases

Bi-Specific Antibodies Therapy Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Bi-Specific Antibodies Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Bi-Specific Antibodies Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Bi-Specific Antibodies Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Bi-Specific Antibodies Therapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Bi-Specific Antibodies Therapy company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Bi-Specific Antibodies Therapy revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Bi-Specific Antibodies Therapy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Fragment-Based Antibodies Major Player Table 3. IgG-Based Antibodies Major Player Table 4. Global Bi-Specific Antibodies Therapy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Cancer Major Player Table 6. Haemophilia Major Player Table 7. Other Non-Cancer Diseases Major Player Table 8. Bi-Specific Antibodies Therapy Industry Trends Table 9. Bi-Specific Antibodies Therapy Industry Drivers Table 10. Bi-Specific Antibodies Therapy Industry Opportunities and Challenges Table 11. Bi-Specific Antibodies Therapy Industry Restraints Table 12. Global Bi-Specific Antibodies Therapy Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Bi-Specific Antibodies Therapy Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Bi-Specific Antibodies Therapy Market Share by Region (2021-2026) Table 15. Global Bi-Specific Antibodies Therapy Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Bi-Specific Antibodies Therapy Market Share by Region (2027-2032) Table 17. Global Bi-Specific Antibodies Therapy Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Bi-Specific Antibodies Therapy Revenue Market Share by Players (2021-2026) Table 19. Global Bi-Specific Antibodies Therapy Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Bi-Specific Antibodies Therapy Key Players Headquarters & Area Served Table 21. Global Bi-Specific Antibodies Therapy Players, Product Type & Application Table 22. Global Bi-Specific Antibodies Therapy Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Bi-Specific Antibodies Therapy by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Bi-Specific Antibodies Therapy Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Bi-Specific Antibodies Therapy Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Bi-Specific Antibodies Therapy Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Bi-Specific Antibodies Therapy Revenue Market Share by Type (2021-2026) Table 29. Global Bi-Specific Antibodies Therapy Revenue Market Share by Type (2027-2032) Table 30. Global Bi-Specific Antibodies Therapy Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Bi-Specific Antibodies Therapy Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Bi-Specific Antibodies Therapy Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Bi-Specific Antibodies Therapy Revenue Market Share by Application (2021-2026) Table 34. Global Bi-Specific Antibodies Therapy Revenue Market Share by Application (2027-2032) Table 35. Alphamab Co. Ltd Company Information Table 36. Alphamab Co. Ltd Business Overview Table 37. Alphamab Co. Ltd Bi-Specific Antibodies Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Alphamab Co. Ltd Bi-Specific Antibodies Therapy Product Portfolio Table 39. Alphamab Co. Ltd Recent Development Table 40. Genmab Company Information Table 41. Genmab Business Overview Table 42. Genmab Bi-Specific Antibodies Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Genmab Bi-Specific Antibodies Therapy Product Portfolio Table 44. Genmab Recent Development Table 45. Lindis Biotech Company Information Table 46. Lindis Biotech Business Overview Table 47. Lindis Biotech Bi-Specific Antibodies Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Lindis Biotech Bi-Specific Antibodies Therapy Product Portfolio Table 49. Lindis Biotech Recent Development Table 50. MacroGenics, Inc Company Information Table 51. MacroGenics, Inc Business Overview Table 52. MacroGenics, Inc Bi-Specific Antibodies Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. MacroGenics, Inc Bi-Specific Antibodies Therapy Product Portfolio Table 54. MacroGenics, Inc Recent Development Table 55. AstraZeneca Company Information Table 56. AstraZeneca Business Overview Table 57. AstraZeneca Bi-Specific Antibodies Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. AstraZeneca Bi-Specific Antibodies Therapy Product Portfolio Table 59. AstraZeneca Recent Development Table 60. AbbVie Company Information Table 61. AbbVie Business Overview Table 62. AbbVie Bi-Specific Antibodies Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. AbbVie Bi-Specific Antibodies Therapy Product Portfolio Table 64. AbbVie Recent Development Table 65. Amgen Company Information Table 66. Amgen Business Overview Table 67. Amgen Bi-Specific Antibodies Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Amgen Bi-Specific Antibodies Therapy Product Portfolio Table 69. Amgen Recent Development Table 70. Pfizer Company Information Table 71. Pfizer Business Overview Table 72. Pfizer Bi-Specific Antibodies Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Pfizer Bi-Specific Antibodies Therapy Product Portfolio Table 74. Pfizer Recent Development Table 75. Akeso, Inc. Company Information Table 76. Akeso, Inc. Business Overview Table 77. Akeso, Inc. Bi-Specific Antibodies Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Akeso, Inc. Bi-Specific Antibodies Therapy Product Portfolio Table 79. Akeso, Inc. Recent Development Table 80. Roche Company Information Table 81. Roche Business Overview Table 82. Roche Bi-Specific Antibodies Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Roche Bi-Specific Antibodies Therapy Product Portfolio Table 84. Roche Recent Development Table 85. Johnson & Johnson Company Information Table 86. Johnson & Johnson Business Overview Table 87. Johnson & Johnson Bi-Specific Antibodies Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Johnson & Johnson Bi-Specific Antibodies Therapy Product Portfolio Table 89. Johnson & Johnson Recent Development Table 90. Sanofi Company Information Table 91. Sanofi Business Overview Table 92. Sanofi Bi-Specific Antibodies Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Sanofi Bi-Specific Antibodies Therapy Product Portfolio Table 94. Sanofi Recent Development Table 95. North America Bi-Specific Antibodies Therapy Revenue by Type (2021-2026) & (US$ Million) Table 96. North America Bi-Specific Antibodies Therapy Revenue by Type (2027-2032) & (US$ Million) Table 97. North America Bi-Specific Antibodies Therapy Revenue by Application (2021-2026) & (US$ Million) Table 98. North America Bi-Specific Antibodies Therapy Revenue by Application (2027-2032) & (US$ Million) Table 99. North America Bi-Specific Antibodies Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 100. North America Bi-Specific Antibodies Therapy Revenue by Country (2021-2026) & (US$ Million) Table 101. North America Bi-Specific Antibodies Therapy Revenue by Country (US$ Million) & (2027-2032) Table 102. Europe Bi-Specific Antibodies Therapy Revenue by Type (2021-2026) & (US$ Million) Table 103. Europe Bi-Specific Antibodies Therapy Revenue by Type (2027-2032) & (US$ Million) Table 104. Europe Bi-Specific Antibodies Therapy Revenue by Application (2021-2026) & (US$ Million) Table 105. Europe Bi-Specific Antibodies Therapy Revenue by Application (2027-2032) & (US$ Million) Table 106. Europe Bi-Specific Antibodies Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 107. Europe Bi-Specific Antibodies Therapy Revenue by Country (2021-2026) & (US$ Million) Table 108. Europe Bi-Specific Antibodies Therapy Revenue by Country (US$ Million) & (2027-2032) Table 109. China Bi-Specific Antibodies Therapy Revenue by Type (2021-2026) & (US$ Million) Table 110. China Bi-Specific Antibodies Therapy Revenue by Type (2027-2032) & (US$ Million) Table 111. China Bi-Specific Antibodies Therapy Revenue by Application (2021-2026) & (US$ Million) Table 112. China Bi-Specific Antibodies Therapy Revenue by Application (2027-2032) & (US$ Million) Table 113. Asia Bi-Specific Antibodies Therapy Revenue by Type (2021-2026) & (US$ Million) Table 114. Asia Bi-Specific Antibodies Therapy Revenue by Type (2027-2032) & (US$ Million) Table 115. Asia Bi-Specific Antibodies Therapy Revenue by Application (2021-2026) & (US$ Million) Table 116. Asia Bi-Specific Antibodies Therapy Revenue by Application (2027-2032) & (US$ Million) Table 117. Asia Bi-Specific Antibodies Therapy Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 118. Asia Bi-Specific Antibodies Therapy Revenue by Region (US$ Million) & (2021-2026) Table 119. Asia Bi-Specific Antibodies Therapy Revenue by Region (US$ Million) & (2027-2032) Table 120. SAMEA Bi-Specific Antibodies Therapy Revenue by Type (2021-2026) & (US$ Million) Table 121. SAMEA Bi-Specific Antibodies Therapy Revenue by Type (2027-2032) & (US$ Million) Table 122. SAMEA Bi-Specific Antibodies Therapy Revenue by Application (2021-2026) & (US$ Million) Table 123. SAMEA Bi-Specific Antibodies Therapy Revenue by Application (2027-2032) & (US$ Million) Table 124. SAMEA Bi-Specific Antibodies Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 125. SAMEA Bi-Specific Antibodies Therapy Revenue by Country (2021-2026) & (US$ Million) Table 126. SAMEA Bi-Specific Antibodies Therapy Revenue by Country (US$ Million) & (2027-2032) Table 127. Research Programs/Design for This Report Table 128. Authors List of This Report Table 129. Secondary Sources Table 130. Primary Sources List of Figures Figure 1. Bi-Specific Antibodies Therapy Image Figure 2. Global Bi-Specific Antibodies Therapy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Bi-Specific Antibodies Therapy Market Size Share 2021 VS 2025 VS 2032 Figure 4. Fragment-Based Antibodies Image Figure 5. IgG-Based Antibodies Image Figure 6. Global Bi-Specific Antibodies Therapy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Bi-Specific Antibodies Therapy Market Size Share 2021 VS 2025 VS 2032 Figure 8. Cancer Image Figure 9. Haemophilia Image Figure 10. Other Non-Cancer Diseases Image Figure 11. Global Bi-Specific Antibodies Therapy Market Size (US$ Million) & (2021-2032) Figure 12. Global Bi-Specific Antibodies Therapy Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Bi-Specific Antibodies Therapy Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Bi-Specific Antibodies Therapy Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Bi-Specific Antibodies Therapy Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Bi-Specific Antibodies Therapy Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Bi-Specific Antibodies Therapy Revenue Market Share by Type (2021-2032) Figure 19. Global Bi-Specific Antibodies Therapy Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Bi-Specific Antibodies Therapy Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Bi-Specific Antibodies Therapy Revenue Market Share by Application (2021-2032) Figure 22. North America Bi-Specific Antibodies Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Bi-Specific Antibodies Therapy Revenue Share by Type (2021-2032) Figure 24. North America Bi-Specific Antibodies Therapy Revenue Share by Application (2021-2032) Figure 25. North America Bi-Specific Antibodies Therapy Revenue Share by Country (2021-2032) Figure 26. United States Bi-Specific Antibodies Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Bi-Specific Antibodies Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Bi-Specific Antibodies Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Bi-Specific Antibodies Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Bi-Specific Antibodies Therapy Revenue Share by Type (2021-2032) Figure 31. Europe Bi-Specific Antibodies Therapy Revenue Share by Application (2021-2032) Figure 32. Europe Bi-Specific Antibodies Therapy Revenue Share by Country (2021-2032) Figure 33. Germany Bi-Specific Antibodies Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Bi-Specific Antibodies Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Bi-Specific Antibodies Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Bi-Specific Antibodies Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Bi-Specific Antibodies Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Bi-Specific Antibodies Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Bi-Specific Antibodies Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Bi-Specific Antibodies Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Bi-Specific Antibodies Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Bi-Specific Antibodies Therapy Revenue Share by Type (2021-2032) Figure 43. China Bi-Specific Antibodies Therapy Revenue Share by Application (2021-2032) Figure 44. Asia Bi-Specific Antibodies Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Bi-Specific Antibodies Therapy Revenue Share by Type (2021-2032) Figure 46. Asia Bi-Specific Antibodies Therapy Revenue Share by Application (2021-2032) Figure 47. Asia Bi-Specific Antibodies Therapy Revenue Share by Region (2021-2032) Figure 48. Japan Bi-Specific Antibodies Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Bi-Specific Antibodies Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Bi-Specific Antibodies Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Bi-Specific Antibodies Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Bi-Specific Antibodies Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Bi-Specific Antibodies Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Bi-Specific Antibodies Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Bi-Specific Antibodies Therapy Revenue Share by Type (2021-2032) Figure 56. SAMEA Bi-Specific Antibodies Therapy Revenue Share by Application (2021-2032) Figure 57. SAMEA Bi-Specific Antibodies Therapy Revenue Share by Country (2021-2032) Figure 58. Brazil Bi-Specific Antibodies Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Bi-Specific Antibodies Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Bi-Specific Antibodies Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Bi-Specific Antibodies Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Bi-Specific Antibodies Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Bi-Specific Antibodies Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Bi-Specific Antibodies Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Bi-Specific Antibodies Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Bi-Specific Antibodies Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Bi-Specific Antibodies Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Bi-Specific Antibodies Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Fragment-Based Antibodies
  • IgG-Based Antibodies
Applications
  • Cancer
  • Haemophilia
  • Other Non-Cancer Diseases
Companies covered
  • Alphamab Co. Ltd
  • Genmab
  • Lindis Biotech
  • MacroGenics, Inc
  • AstraZeneca
  • AbbVie
  • Amgen
  • Pfizer
  • Akeso, Inc.
  • Roche
  • Johnson & Johnson
  • Sanofi

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Bi-Specific Antibodies Therapy Market by Type
  3. 1.2.1 Global Bi-Specific Antibodies Therapy Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Fragment-Based Antibodies
  5. 1.2.3 IgG-Based Antibodies
  6. 1.3 Bi-Specific Antibodies Therapy Market by Application
  7. 1.3.1 Global Bi-Specific Antibodies Therapy Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Cancer
  9. 1.3.3 Haemophilia
  10. 1.3.4 Other Non-Cancer Diseases
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Bi-Specific Antibodies Therapy Market Dynamics
  1. 2.1 Bi-Specific Antibodies Therapy Industry Trends
  2. 2.2 Bi-Specific Antibodies Therapy Industry Drivers
  3. 2.3 Bi-Specific Antibodies Therapy Industry Opportunities and Challenges
  4. 2.4 Bi-Specific Antibodies Therapy Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Bi-Specific Antibodies Therapy Market Perspective (2021-2032)
  2. 3.2 Global Bi-Specific Antibodies Therapy Growth Trends by Region
  3. 3.2.1 Global Bi-Specific Antibodies Therapy Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Bi-Specific Antibodies Therapy Market Size by Region (2021-2026)
  5. 3.2.3 Global Bi-Specific Antibodies Therapy Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Bi-Specific Antibodies Therapy Revenue by Players
  2. 4.1.1 Global Bi-Specific Antibodies Therapy Revenue by Players (2021-2026)
  3. 4.1.2 Global Bi-Specific Antibodies Therapy Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Bi-Specific Antibodies Therapy Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Bi-Specific Antibodies Therapy Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Bi-Specific Antibodies Therapy Key Players Headquarters & Area Served
  7. 4.4 Global Bi-Specific Antibodies Therapy Players, Product Type & Application
  8. 4.5 Global Bi-Specific Antibodies Therapy Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Bi-Specific Antibodies Therapy Market CR5 and HHI
  11. 4.6.3 2025 Bi-Specific Antibodies Therapy Tier 1, Tier 2, and Tier 3
5 Bi-Specific Antibodies Therapy Market Size by Type
  1. 5.1 Global Bi-Specific Antibodies Therapy Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Bi-Specific Antibodies Therapy Revenue by Type (2021-2032)
  3. 5.3 Global Bi-Specific Antibodies Therapy Revenue Market Share by Type (2021-2032)
6 Bi-Specific Antibodies Therapy Market Size by Application
  1. 6.1 Global Bi-Specific Antibodies Therapy Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Bi-Specific Antibodies Therapy Revenue by Application (2021-2032)
  3. 6.3 Global Bi-Specific Antibodies Therapy Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Alphamab Co. Ltd
  2. 7.1.1 Alphamab Co. Ltd Company Information
  3. 7.1.2 Alphamab Co. Ltd Business Overview
  4. 7.1.3 Alphamab Co. Ltd Bi-Specific Antibodies Therapy Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Alphamab Co. Ltd Bi-Specific Antibodies Therapy Product Portfolio
  6. 7.1.5 Alphamab Co. Ltd Recent Developments
  7. 7.2 Genmab
  8. 7.2.1 Genmab Company Information
  9. 7.2.2 Genmab Business Overview
  10. 7.2.3 Genmab Bi-Specific Antibodies Therapy Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Genmab Bi-Specific Antibodies Therapy Product Portfolio
  12. 7.2.5 Genmab Recent Developments
  13. 7.3 Lindis Biotech
  14. 7.3.1 Lindis Biotech Company Information
  15. 7.3.2 Lindis Biotech Business Overview
  16. 7.3.3 Lindis Biotech Bi-Specific Antibodies Therapy Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Lindis Biotech Bi-Specific Antibodies Therapy Product Portfolio
  18. 7.3.5 Lindis Biotech Recent Developments
  19. 7.4 MacroGenics, Inc
  20. 7.4.1 MacroGenics, Inc Company Information
  21. 7.4.2 MacroGenics, Inc Business Overview
  22. 7.4.3 MacroGenics, Inc Bi-Specific Antibodies Therapy Revenue and Gross Margin (2021-2026)
  23. 7.4.4 MacroGenics, Inc Bi-Specific Antibodies Therapy Product Portfolio
  24. 7.4.5 MacroGenics, Inc Recent Developments
  25. 7.5 AstraZeneca
  26. 7.5.1 AstraZeneca Company Information
  27. 7.5.2 AstraZeneca Business Overview
  28. 7.5.3 AstraZeneca Bi-Specific Antibodies Therapy Revenue and Gross Margin (2021-2026)
  29. 7.5.4 AstraZeneca Bi-Specific Antibodies Therapy Product Portfolio
  30. 7.5.5 AstraZeneca Recent Developments
  31. 7.6 AbbVie
  32. 7.6.1 AbbVie Company Information
  33. 7.6.2 AbbVie Business Overview
  34. 7.6.3 AbbVie Bi-Specific Antibodies Therapy Revenue and Gross Margin (2021-2026)
  35. 7.6.4 AbbVie Bi-Specific Antibodies Therapy Product Portfolio
  36. 7.6.5 AbbVie Recent Developments
  37. 7.7 Amgen
  38. 7.7.1 Amgen Company Information
  39. 7.7.2 Amgen Business Overview
  40. 7.7.3 Amgen Bi-Specific Antibodies Therapy Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Amgen Bi-Specific Antibodies Therapy Product Portfolio
  42. 7.7.5 Amgen Recent Developments
  43. 7.8 Pfizer
  44. 7.8.1 Pfizer Company Information
  45. 7.8.2 Pfizer Business Overview
  46. 7.8.3 Pfizer Bi-Specific Antibodies Therapy Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Pfizer Bi-Specific Antibodies Therapy Product Portfolio
  48. 7.8.5 Pfizer Recent Developments
  49. 7.9 Akeso, Inc.
  50. 7.9.1 Akeso, Inc. Company Information
  51. 7.9.2 Akeso, Inc. Business Overview
  52. 7.9.3 Akeso, Inc. Bi-Specific Antibodies Therapy Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Akeso, Inc. Bi-Specific Antibodies Therapy Product Portfolio
  54. 7.9.5 Akeso, Inc. Recent Developments
  55. 7.10 Roche
  56. 7.10.1 Roche Company Information
  57. 7.10.2 Roche Business Overview
  58. 7.10.3 Roche Bi-Specific Antibodies Therapy Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Roche Bi-Specific Antibodies Therapy Product Portfolio
  60. 7.10.5 Roche Recent Developments
  61. 7.11 Johnson & Johnson
  62. 7.11.1 Johnson & Johnson Company Information
  63. 7.11.2 Johnson & Johnson Business Overview
  64. 7.11.3 Johnson & Johnson Bi-Specific Antibodies Therapy Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Johnson & Johnson Bi-Specific Antibodies Therapy Product Portfolio
  66. 7.11.5 Johnson & Johnson Recent Developments
  67. 7.12 Sanofi
  68. 7.12.1 Sanofi Company Information
  69. 7.12.2 Sanofi Business Overview
  70. 7.12.3 Sanofi Bi-Specific Antibodies Therapy Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Sanofi Bi-Specific Antibodies Therapy Product Portfolio
  72. 7.12.5 Sanofi Recent Developments
8 North America
  1. 8.1 North America Bi-Specific Antibodies Therapy Revenue (2021-2032)
  2. 8.2 North America Bi-Specific Antibodies Therapy Revenue by Type (2021-2032)
  3. 8.2.1 North America Bi-Specific Antibodies Therapy Revenue by Type (2021-2026)
  4. 8.2.2 North America Bi-Specific Antibodies Therapy Revenue by Type (2027-2032)
  5. 8.3 North America Bi-Specific Antibodies Therapy Revenue Share by Type (2021-2032)
  6. 8.4 North America Bi-Specific Antibodies Therapy Revenue by Application (2021-2032)
  7. 8.4.1 North America Bi-Specific Antibodies Therapy Revenue by Application (2021-2026)
  8. 8.4.2 North America Bi-Specific Antibodies Therapy Revenue by Application (2027-2032)
  9. 8.5 North America Bi-Specific Antibodies Therapy Revenue Share by Application (2021-2032)
  10. 8.6 North America Bi-Specific Antibodies Therapy Revenue by Country
  11. 8.6.1 North America Bi-Specific Antibodies Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Bi-Specific Antibodies Therapy Revenue by Country (2021-2026)
  13. 8.6.3 North America Bi-Specific Antibodies Therapy Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Bi-Specific Antibodies Therapy Revenue (2021-2032)
  2. 9.2 Europe Bi-Specific Antibodies Therapy Revenue by Type (2021-2032)
  3. 9.2.1 Europe Bi-Specific Antibodies Therapy Revenue by Type (2021-2026)
  4. 9.2.2 Europe Bi-Specific Antibodies Therapy Revenue by Type (2027-2032)
  5. 9.3 Europe Bi-Specific Antibodies Therapy Revenue Share by Type (2021-2032)
  6. 9.4 Europe Bi-Specific Antibodies Therapy Revenue by Application (2021-2032)
  7. 9.4.1 Europe Bi-Specific Antibodies Therapy Revenue by Application (2021-2026)
  8. 9.4.2 Europe Bi-Specific Antibodies Therapy Revenue by Application (2027-2032)
  9. 9.5 Europe Bi-Specific Antibodies Therapy Revenue Share by Application (2021-2032)
  10. 9.6 Europe Bi-Specific Antibodies Therapy Revenue by Country
  11. 9.6.1 Europe Bi-Specific Antibodies Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Bi-Specific Antibodies Therapy Revenue by Country (2021-2026)
  13. 9.6.3 Europe Bi-Specific Antibodies Therapy Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
  19. 9.6.9 Nordic Countries
10 China
  1. 10.1 China Bi-Specific Antibodies Therapy Revenue (2021-2032)
  2. 10.2 China Bi-Specific Antibodies Therapy Revenue by Type (2021-2032)
  3. 10.2.1 China Bi-Specific Antibodies Therapy Revenue by Type (2021-2026)
  4. 10.2.2 China Bi-Specific Antibodies Therapy Revenue by Type (2027-2032)
  5. 10.3 China Bi-Specific Antibodies Therapy Revenue Share by Type (2021-2032)
  6. 10.4 China Bi-Specific Antibodies Therapy Revenue by Application (2021-2032)
  7. 10.4.1 China Bi-Specific Antibodies Therapy Revenue by Application (2021-2026)
  8. 10.4.2 China Bi-Specific Antibodies Therapy Revenue by Application (2027-2032)
  9. 10.5 China Bi-Specific Antibodies Therapy Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Bi-Specific Antibodies Therapy Revenue (2021-2032)
  2. 11.2 Asia Bi-Specific Antibodies Therapy Revenue by Type (2021-2032)
  3. 11.2.1 Asia Bi-Specific Antibodies Therapy Revenue by Type (2021-2026)
  4. 11.2.2 Asia Bi-Specific Antibodies Therapy Revenue by Type (2027-2032)
  5. 11.3 Asia Bi-Specific Antibodies Therapy Revenue Share by Type (2021-2032)
  6. 11.4 Asia Bi-Specific Antibodies Therapy Revenue by Application (2021-2032)
  7. 11.4.1 Asia Bi-Specific Antibodies Therapy Revenue by Application (2021-2026)
  8. 11.4.2 Asia Bi-Specific Antibodies Therapy Revenue by Application (2027-2032)
  9. 11.5 Asia Bi-Specific Antibodies Therapy Revenue Share by Application (2021-2032)
  10. 11.6 Asia Bi-Specific Antibodies Therapy Revenue by Country
  11. 11.6.1 Asia Bi-Specific Antibodies Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Bi-Specific Antibodies Therapy Revenue by Country (2021-2026)
  13. 11.6.3 Asia Bi-Specific Antibodies Therapy Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Bi-Specific Antibodies Therapy Revenue (2021-2032)
  2. 12.2 SAMEA Bi-Specific Antibodies Therapy Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Bi-Specific Antibodies Therapy Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Bi-Specific Antibodies Therapy Revenue by Type (2027-2032)
  5. 12.3 SAMEA Bi-Specific Antibodies Therapy Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Bi-Specific Antibodies Therapy Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Bi-Specific Antibodies Therapy Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Bi-Specific Antibodies Therapy Revenue by Application (2027-2032)
  9. 12.5 SAMEA Bi-Specific Antibodies Therapy Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Bi-Specific Antibodies Therapy Revenue by Country
  11. 12.6.1 SAMEA Bi-Specific Antibodies Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Bi-Specific Antibodies Therapy Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Bi-Specific Antibodies Therapy Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst